Eosinophilia is common in myeloproliferative disorders (MPD) with abnormalities of chromosome band 5q31-33, including those that present with t(1;5)(q23;q33). With the development of rational drug therapy, characterization of the molecular targets for these translocations could guide treatment and impact on patient survival. We cloned the t(1;5)(q23;q33) and showed that it fuses PDGFRB to the coiled-coil domains of a novel partner protein, Myomegalin. Using two-color interphase FISH, we also demonstrated that the eosinophils are clonal in these disorders. Imatinib mesylate has recently been shown to be efficacious in MPDs with PDGFR activation. Therefore, following our molecular studies, we were able to redirect this patient's treatment. Although she had refractory and progressive disease, once imatinib was started complete clinical and hematological remission, and major cytogenetic response was achieved. Given the therapeutic implications, our findings stress the need to aggressively investigate the molecular basis of these diseases, with emphasis on the PDGFR family.
ABSTRACT:
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INTRODUCTION:
The cloning of genes affected by recurrent chromosomal translocations has furthered our understanding of the molecular basis of hematological malignancies, and allowed the development of molecular assays that have improved diagnosis and monitoring of therapy. It has also led to the development of rational targeted drug therapy, including the specific tyrosine kinase inhibitor, imatinib mesylate 1 (Gleevec, Novartis).
Eosinophilia is common in several myeloproliferative disorders (MPD), notably chronic myeloid leukemia (CML) and the 8p11 myeloproliferative syndrome 2, 3 . Less common causes of eosinophilia include MPDs associated with translocations involving chromosome band 5q31-33 4 . Cloning of these translocations [4] [5] [6] [7] [8] [9] showed that they consistently target the PDGFRB gene. In all cases, partner genes contribute oligomerization domains that constitutively activate PDGFRB's tyrosine kinase. Recently, cryptic deletions of chromosome 4q12 resulting in activation of PDGFRA were found in cases of hypereosinophilic syndrome (HES) 10 , suggesting that activation of the PDGFR receptor tyrosine kinase family is a common theme in this phenotypically similar collection of disorders.
Of the MPDs with eosinophilia, one unique sub-group presents with a t(1;5)(q23;q33) 11, 12 . Here, we describe the molecular cloning of this translocation and the clinical/translational consequences of this finding. etoposide, cytarabine and interferon. At the start of imatinib, one year after the diagnosis, the patient had progressive disease, and a new cytogenetic study confirmed the presence of the t(1;5) in 100% of metaphases.
All of the laboratory investigations and treatment decisions were approved by the ethics committee of the patient's institution of origin (Hospital AC Camargo, Brazil).
Written consent was obtained from the patient's guardians.
Molecular cloning:
Southern blot and 5' RACE PCR were performed as described previously 3, 13 . Appropriate PCR products were cloned and sequenced.
RT-PCR:
Single step RT-PCR was used for detection of the PDE4DIP -PDGFRB and reciprocal PDGRFB-PDE4DIP fusions . To define the specific PDE4DIP ( Myomegalin) isoform fused to PDGFRB, a long-range nested RT-PCR was performed. All oligos sequences are available upon request. All relevant PCR products were sequenced.
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Two-color fluorescence in-situ hybridization:
An eosinophil-enriched cell population was isolated from the patient's peripheral blood as described previously 14 . BAC clones mapping centromeric (CTC-307M15, CTB-46E9, and CTB -13H5) and telomeric (CTB-5M9, CTB-108B20, and CTB-171P15) to the PDGFRB locus were from ResGen (Carlsbad, CA). BAC DNAs were hybridized to the patient's slides as described previously 3 . After counterstaining with DAPI, images were processed using an Olympus AX70 fluorescence microscope and Genus imaging software (Applied Imaging). To assess post-treatment samples for cytogenetic response, cells were spun onto slides, fixed, and hybridized to PDGFRB probes as described above. Cells were scored for the presence of PDGFRB rearrangements on the BioView Duet Imaging system (Rehovot, Israel).
RESULTS AND DISCUSSION
PDGFRB is fused to a novel gene, PDE4DIP, in the t(1;5)(q23;q33). With
Southern blot analysis, we detected rearrangement of the PDGRFB gene in the t(1;5) DNA ( Figure 1A ). Subsequently, sequencing of several 5' RACE-PCR clones consistently showed the same novel DNA sequence fused in-frame to PDGFRB exon 11.
For
Database search confirmed that these sequences mapped to chromosome 1q21-23 and corresponded to a novel gene, PDE4DIP (phosphodiesterase 4D interacting protein , myomegalin) 15 . Southern blot analysis with a PDE4DIP probe confirmed its disruption in this translocation (data not shown).
The chimeric PDE4DIP-PDGFRB mRNA was readily detectable in the patient with the t(1;5)(q23;q33), but not in two normal controls ( Figure 1B) . The reciprocal PDGFRB-PDE4DIP fusion is not expressed ( Figure 1B) . Myomegalin is the protein encoded by PDE4DIP and it was characterized because of its binding to the phosphodiesterase PDE4D 14 . Of relevance for this report, myomegalin encodes several putative oligomerization domains capable of activating PDGFRB. They include a leucine z ipper (LZ) domain and several coiled-coil structures (Fig. 1C) . In humans, there are at least two major isoforms of myomegalin (KIAA0454 and KIAA0477) 15 , encoding unique N and C termini ( Figure 1C ). This feature is of significance because one of these isoforms encodes an N-terminal LZ domain. Surprisingly, we found that in our case PDGFRB is fused to the PDE4DIP isoform lacking the LZ domain (KIAA0477) ( Figure 1C ) indirectly implicating the coiled-coils domains in the constitutive activation of PDGFRB.
In summary, in this fusion protein the first 905 amino acids of myomegalin are joined in-frame to the transmembrane and tyrosine kinase domains of PDGFRB ( Figure   1D ). It is highly likely that deregulation of PDGFRB activity is the major pathogenic defect in this MPD.
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In MPD with t(1;5)(q23;q33) the eosinophils are part of the malignant clone.
Eosinophilia is a common feature of several hematological malignancies. It is generally assumed that, when a clonal cytogenetic abnormality has been demonstrated in a MDS/MPD with eosinophilia, these cells are part of the neoplastic clone. However, this is not always true [16] [17] [18] , and only rarely has the clonality of the eosinophils been clearly established 19 . As seen in figure 2 , eosinophils are readily identified based on the autofluorescent of eosinophilic granules, a feature that is unique among cells of the granulocytic series [19] [20] [21] . These granules were pseudo-colorized white to allow for clear Figure   1E ). Since AKT is one of the well-defined targets of PDGFRB mitogenic and transforming effects in hematopoietic cells, via activation of the PI3K pathway 4 , these studies are consistent with imatinib specifically targeting the deregulated PDGFRB in this patient's MPD.
In summary, we have shown that the t(1;5)(q23;q33) targets PDGFRB and that complete remission can be achieved with imatinib in a heavily pre-treated patient with progressive disease. Of interest, although only a few cases of MPD with t(1;5)(q23;q33) have been described 11, 12 this disease appears to be more common in infants; it also lacks the extreme male bias found in other cases MPD associated with PDGRB activation 4 
